Fumarranol Explained

Fumarranol is a drug which acts as an inhibitor of the type 2 methionine aminopeptidase enzyme METAP2. It was derived by structural modification of the natural product fumagillin. It was originally developed as an anti-angiogenesis drug for the treatment of cancer,^[1] but it was subsequently found to bind with high affinity to the METAP2 enzyme in malaria parasites and has been investigated as a potential treatment for malaria.^{[2] [3]}

See also

• Beloranib

Notes and References

1. Lu J, Chong CR, Hu X, Liu JO . Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo . Journal of Medicinal Chemistry . 49 . 19 . 5645–8 . September 2006 . 16970390 . 10.1021/jm060559v .
2. Chen X, Xie S, Bhat S, Kumar N, Shapiro TA, Liu JO . Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo . Chemistry & Biology . 16 . 2 . 193–202 . February 2009 . 19246010 . 10.1016/j.chembiol.2009.01.006 .
3. Deu E . Proteases as antimalarial targets: strategies for genetic, chemical, and therapeutic validation . The FEBS Journal . 284 . 16 . 2604–2628 . August 2017 . 28599096 . 5575534 . 10.1111/febs.14130 .